India Pesticides Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/hy5ht1qfqbfnu0bwvymz7k5u.pdf

Key Takeaways


Demand & Order Book

D. K. Jain: "No, sir, we are not getting any such requests from any of our customers across the world. On the other hand, we are getting requests from the customers to increase the capacity, increased requirements are there, we have not received from any customer, any request for reducing the supplies."

Margin Dynamics & Cost Headwinds

D.K. Jain: "Now, because we are adding few more new molecules, the new molecules, there is some certain degree of uncertainty would be there, isn't it? So, we try to get to as much as possible, but we feel that at least we should be able to maintain this range."

Capacity Expansion: Sandila & Hamirpur


New Product Pipeline & R&D

D. K. Jain: "Though we try to make as much as possible our normal criteria is that the raw material should not be more than 50% and until now we have been able to maintain that... if we don't find the product to be in that range and it is very much out from that point, then we don't take up that product at all..."

Balance Sheet & Working Capital


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth20–25% annual growth rateComing 3–5 years
EBITDA marginMaintain 26–27% range, with one or two points variation possibleOngoing
Sandila Block 1 commissioningNew manufacturing block (part of 4,000 MT addition)September 2022
Sandila Block 2 commissioningSecond new manufacturing blockJanuary 2023
Remaining IPO moleculesTwo more molecules to be launchedDuring remaining part of FY23
New product revenue contributionAt least ₹100 crore from new moleculesBy FY23 year-end
Hamirpur environmental clearanceEIA report submission by August end; clearance expectedOctober/November 2022
Hamirpur first revenueSome revenue from the new siteFY24 third to fourth quarter
Hamirpur annual capex₹100–125 crore per yearComing 3–4 years
FY24 revenue from existing facilitiesAlmost ₹1,000 crore at 2.5x asset turnover on ~₹140 crore total capexFY24
Pretilachlor Phase 2Work to commence on second phase of backward integrationLater part of current fiscal year

Key Metrics

MetricQ1 FY23
Total revenue₹221 crore, +27.4% YoY
EBITDA₹59 crore
EBITDA margin26.6%
PAT₹41 crore, vs ₹42 crore in Q1 FY22
PAT margin18.5%
Export revenue₹101 crore, vs ₹64 crore in Q1 FY22
Domestic revenue₹118 crore, vs ₹106 crore in Q1 FY22
Technical revenue₹170 crore
Formulation revenue₹48 crore
Revenue growth target20-25% annually, for the coming 3-5 years
EBITDA margin guidance26-27%
Volume growth21% YoY
Capacity utilization~80%, vs ~65% in Q4 FY22
Installed technical capacity23,500 metric tons, up from 19,500 metric tons last year
New products revenue contribution~₹22 crore, 10% of total revenue
New molecules launched in Q16
Net cash~₹105 crore, as of June 30 (debt ~₹20 crore, FD and bank balance ~₹125 crore)
Capex incurred in Q1₹17 crore
FY23 planned capex (Sandila)₹70 crore
FY23 planned capex (Hamirpur)~₹20 crore
Gross margin~50%
Formulation share of total turnover22%
Energy cost increase impact~₹4.5 crore incremental in Q1, rice husk prices up ~200% YoY
Herbicide product (Australia) revenue share~15% of total revenue in Q1
Expected new products contribution by FY23 year-endAt least ₹100 crore